SCHEMBL3265682

SCHEMBL3265682

NC(=O)COC(=O)NCCC1CCN(c2cc(C(F)(F)F)ccn2)CC1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CHRM4 P08173 5/20 0.58
CHRM2 P08172 2/20 0.49
CHRM1 P11229 2/20 0.49
CHRM3 P20309 1/20 0.49
FFAR4 Q5NUL3 1/20 0.48
HRH3 Q9Y5N1 1/20 0.46
ADRB1 P08588 1/20 0.46
FFAR1 O14842 1/20 0.45
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
MAPT P10636 1/20 0.43
DPP4 P27487 1/20 0.42
DPP7 Q9UHL4 1/20 0.42
ACACB O00763 1/20 0.42
LCAT P04180 2/20 0.41
SIRT2 Q8IXJ6 2/20 0.41
SIRT1 Q96EB6 2/20 0.41
SIRT3 Q9NTG7 2/20 0.41
CETP P11597 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3265679 0.91 CHRM4 (0.50) CHRM4CHRM2CHRM1CHRM3FFAR4
SCHEMBL3269081 0.85 CHRM4 (0.57) CHRM4CHRM2CHRM1CHRM3KDM4E
SCHEMBL3265698 0.84 CHRM4 (0.48) CHRM4CHRM2CHRM1CHRM3SIRT2
SCHEMBL1728821 0.84 CHRM4 (0.68) CHRM4CHRM2CHRM1CHRM3FFAR4
SCHEMBL240152 0.83 CHRM4 (0.56) CHRM4CHRM2CHRM1HRH3ALDH1A1
SCHEMBL3270012 0.81 KDM4E (0.49) KDM4EALDH1A1MAPT
SCHEMBL3265663 0.80 CHRM4 (0.44) CHRM4CHRM2CHRM1SIRT2SIRT1
SCHEMBL3269077 0.77 CHRM4 (0.49) CHRM4CHRM2CHRM1KDM4ESIRT2
SCHEMBL3266256 0.77 DEGS1 (0.48) CHRM4CHRM2CHRM1KDM4EMAPT
SCHEMBL3266210 0.77 CHRM4 (0.45) CHRM4CHRM2CHRM1CHRM3HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120004207-A1 THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES SANOFI-AVENTIS (FR) 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004207-A1 THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES CLCN2, CLIC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 CHRM4 243/4885CHRM2 17/4885CHRM1 45/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.